13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      LncRNA HCP5 Stimulates the Proliferation of Non-Small Cell Lung Cancer Cells by Up-Regulating Survivin Through the Down-Regulation of miR-320

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          We explored the roles of lncRNA HCP5 in non-small cell lung cancer (NSCLC).

          Methods

          Levels of HCP5 were measured by performing qPCR and data were compared between non-tumor and NSCLC tissue samples by performing a paired t-test. Expression levels of miR-320 and survivin mRNA in NSCLC tissues were also measured by performing qPCR. The effects of HCP5, miR-320 and survivin overexpression on the proliferation of H23 cells were analyzed by cell proliferation assay.

          Results

          We found that HCP5 was up-regulated in NSCLC and predicted the poor survival of NSCLC patients. HCP5 was negatively correlated with miR-320 but positively correlated with survivin in NSCLC tissues. In NSCLC cells, HCP5 overexpression led to the up-regulated survivin and down-regulated miR-320. Moreover, miR-320 overexpression failed to affect HCP5 but down-regulated survivin. Cell proliferation assay showed that HCP5 and survivin overexpression led to increased, while miR-320 overexpression led to decreased cell proliferation rate. In addition, miR-320 overexpression reduced the effects of HCP5 overexpression.

          Conclusion

          Therefore, HCP5 may stimulate the proliferation of NSCLC cells by up-regulating survivin through the down-regulation of miR-320.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          MicroRNA biogenesis: coordinated cropping and dicing.

          V Kim (2005)
          The recent discovery of microRNAs (miRNAs) took many by surprise because of their unorthodox features and widespread functions. These tiny, approximately 22-nucleotide, RNAs control several pathways including developmental timing, haematopoiesis, organogenesis, apoptosis, cell proliferation and possibly even tumorigenesis. Among the most pressing questions regarding this unusual class of regulatory miRNA-encoding genes is how miRNAs are produced in cells and how the genes themselves are controlled by various regulatory networks.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Cancer statistics for Hispanics/Latinos, 2018.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge

              Long non-coding RNAs (lncRNAs), which are important functional regulators in cancer, have received increased attention in recent years. In this study, next-generation sequencing technology was used to identify aberrantly expressed lncRNAs in follicular thyroid carcinoma (FTC). The long non-coding RNA–HLA complex P5 (HCP5) was found to be overexpressed in FTC. The results of the qPCR analysis were consistent with the sequencing results. In addition, functional experiments showed that overexpression of HCP5 can promote the proliferation, migration, invasiveness and angiogenic ability of FTC cells. Furthermore, according to the sequencing results, HCP5 and alpha-2, 6-sialyltransferase 2 (ST6GAL2) were co-expressed in FTC. We hypothesised that ST6GAL2 may be regulated by HCP5, which would in turn mediate the activity of FTC cells. Through qPCR, immunostaining analyses and functional experiments, we determined that the expression of HCP5 was elevated and was correlated with the levels of ST6GAL2 in FTC tissues and cells. Mechanistic experiments showed that HCP5 functions as a competing endogenous RNA (ceRNA) and acts as a sponge for miR-22-3p, miR-186-5p and miR-216a-5p, which activates ST6GAL2. In summary, our study revealed that HCP5 is a tumour regulator in the development of FTC and that it may contribute to improvement of FTC diagnosis and therapy.
                Bookmark

                Author and article information

                Journal
                Cancer Manag Res
                Cancer Manag Res
                CMAR
                cancmanres
                Cancer Management and Research
                Dove
                1179-1322
                14 February 2020
                2020
                : 12
                : 1129-1134
                Affiliations
                [1 ]Oncology Department, Second People’s Hospital of Jingmen , Jingmen City, Hubei Province 448000, People’s Republic of China
                [2 ]Department of Oncology, The Central Hospital of Wuhan Affiliated to Tongji Medical College, Huazhong University of Science and Technology , Wuhan City, Hubei Province 430061, People’s Republic of China
                [3 ]Department of Traditional Chinese Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Art and Science , Xiangyang City, Hubei Province 441021, People’s Republic of China
                Author notes
                Correspondence: Li Chen Department of Traditional Chinese Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Art and Science , Jingzhou Street 136#, Xiangyang City, Hubei Province441021, People’s Republic of ChinaTel +86 0710-3522791 Email ojeupkwmky83@163.com
                Article
                222221
                10.2147/CMAR.S222221
                7028385
                32104093
                3e1a133d-ab82-413d-93ef-2648f5d2845a
                © 2020 Li et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 06 July 2019
                : 10 October 2019
                Page count
                Figures: 4, References: 18, Pages: 6
                Categories
                Original Research

                Oncology & Radiotherapy
                hcp5,non-small cell lung cancer,mir-320,survivin
                Oncology & Radiotherapy
                hcp5, non-small cell lung cancer, mir-320, survivin

                Comments

                Comment on this article